Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HCC × atezolizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 109 Carcinoma, Hepatocellular 63 Neoplasms 44 Breast Neoplasms 43 Small Cell Lung Carcinoma 41 Lung Neoplasms 37 Triple Negative Breast Neoplasms 32 Melanoma 31 Colorectal Neoplasms 31 Carcinoma, Transitional Cell 31 Urinary Bladder Neoplasms 29 Neoplasm Metastasis 27 Carcinoma, Renal Cell 22 Ovarian Neoplasms 18 Stomach Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 14 Head and Neck Neoplasms 14 Uterine Cervical Neoplasms 13 Liver Neoplasms 12 Recurrence 10 Prostatic Neoplasms 10 Lymphoma 9 Glioblastoma 9 Solid Tumors 8 Sarcoma 8 Pancreatic Neoplasms 8 Esophageal Neoplasms 8 Kidney Neoplasms 7 Carcinoma, Merkel Cell 7 Solid Tumor 6

Interventions

nimotuzumab 1 atezolizumab 1 Tirapazamine 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡